861393-81-9

Usage

Structure

A derivative of benzodioxin with a fused dioxin ring and an acetamide group attached to the 6th position

Usage

Pharmaceutical research as a precursor for the synthesis of various drugs and pharmaceutical compounds

Properties

Potential anti-inflammatory and analgesic properties

Health Risks

May pose health risks if not properly managed

Precautions

Handle with caution to avoid exposure and ensure proper safety measures are in place during synthesis and use

Applications

Valuable component in drug development due to its potential therapeutic properties

Chemical Class

Heteroaromatic compound with oxygen and nitrogen atoms in the ring structure

Solubility

Solubility in organic solvents such as ethanol, methanol, and acetone, but may vary depending on the specific conditions and solvent used

Upstream product

• 108704-93-4 2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetyl chloride 
• 22013-33-8 6-amino-3,4-benzodioxane 

Relevant academic research and scientific papers

Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain

We disclose the design of a novel series of cyanoguanidines that are potent (IC50 ? 10-100 nM) and selective (≥100-fold) P2X7 receptor antagonists against the other P2 receptor subtypes such as the P2Y2, P2X4, and P2X3. We also found that these P2X7 antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 μmol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X7 receptors in neuropathic pain and therefore a potential use of P2X7 antagonists as novel therapeutic tools for the treatment of this type of pain.

Cyanoamidine P2X7 antagonists for the treatment of pain

Novel cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R1-R12 are as defined in the specification act as antagonists of the P2X7 receptor. These compounds are particularly useful in the treatment of pain, inflammation and neurodegeneration states.

P2X7 antagonists for treating neuropathic pain

The present invention discloses a method for treating neuropathic pain using compounds of formula I or compositions containing compounds of formula I.

Substituted quinazolines and analogs and use thereof

The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.